Market Place
Sourcing Support
GlycoMimetics to Present Uproleselan Data at ASH Annual Meeting
06 Nov 2024 //
BUSINESSWIRE
GlycoMimetics Uproleselan Study Did Not Meet Primary Endpoint
29 Oct 2024 //
BUSINESSWIRE
GlycoMimetics Enters Acquisition Agreement With Crescent Biopharma
29 Oct 2024 //
BUSINESSWIRE
GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan
25 Jul 2024 //
BUSINESSWIRE
GlycoMimetics: Pivotal Phase 3 Results Of Uproleselan In R/R AML
04 Jun 2024 //
BUSINESSWIRE
GlycoMimetics KOL Event On Uproleselan Phase 3 Data In R/R AML
29 May 2024 //
BUSINESSWIRE
GlycoMimetics reports Phase 3 results for Uproleselan in AML.
06 May 2024 //
BUSINESSWIRE
GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
25 Apr 2024 //
BUSINESSWIRE
GlycoMimetics Reports Highlights and Financial Results 2023
27 Mar 2024 //
BUSINESSWIRE
GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results
13 Mar 2024 //
BUSINESSWIRE
GlycoMimetics to Participate in Cowen 44th Annual Health Care Conference
26 Feb 2024 //
BUSINESSWIRE
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
12 Feb 2024 //
BUSINESSWIRE
GlycoMimetics Announces Positive Results from Phase 1a of GMI-1687
04 Jan 2024 //
BUSINESSWIRE
GlycoMimetics Announces Independent Presentations on Uproleselan
10 Dec 2023 //
BUSINESSWIRE
GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference
09 Nov 2023 //
BUSINESSWIRE
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023
03 Nov 2023 //
BUSINESSWIRE
GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023
20 Oct 2023 //
BUSINESSWIRE
GlycoMimetics to Participate in H.C. Wainwright 25th Investment Conference
05 Sep 2023 //
BUSINESSWIRE
GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
17 Aug 2023 //
BUSINESSWIRE
GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023
19 Jul 2023 //
BUSINESSWIRE
GlycoMimetics Announces Its Addition to the Russell Microcap® Index
26 Jun 2023 //
BUSINESSWIRE
GlycoMimetics Announces U.S. FDA Clears Study of Uproleselan
15 Jun 2023 //
BUSINESSWIRE
GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference
31 May 2023 //
BUSINESSWIRE
GlycoMimetics Reports Highlights and Financial Results for 1Q 2023
03 May 2023 //
BUSINESSWIRE
GlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023
26 Apr 2023 //
BUSINESSWIRE
GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results
16 Mar 2023 //
BUSINESSWIRE
GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
16 Feb 2023 //
BUSINESSWIRE
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
06 Feb 2023 //
BUSINESSWIRE
GlycoMimetics Announces Data in Frontline Unfit & Acute Myeloid Leukemia
12 Dec 2022 //
BUSINESSWIRE
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2022
09 Nov 2022 //
BUSINESSWIRE
GlycoMimetics to Participate in Two Upcoming Investor Conferences
08 Nov 2022 //
BUSINESSWIRE
GlycoMimetics to Report Third Quarter Financial Results on November 9, 2022
02 Nov 2022 //
BUSINESSWIRE
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
09 Sep 2022 //
BUSINESSWIRE
GlycoMimetics to Participate in Upcoming H.C. Wainwright Global Conference
07 Sep 2022 //
BUSINESSWIRE
GlycoMimetics Appoints Edwin Rock, M.D., Ph.D. as Chief Medical Officer
06 Sep 2022 //
BUSINESSWIRE
GlycoMimetics to Report Second Quarter Financial Results on August 3, 2022
27 Jul 2022 //
BUSINESSWIRE
GlycoMimetics to Participate at Upcoming Jefferies 2022 Healthcare Conference
02 Jun 2022 //
BUSINESSWIRE
GlycoMimetics Reports Highlights and Financial Results for First Quarter 2022
28 Apr 2022 //
BUSINESSWIRE
GlycoMimetics to Participate at Upcoming Roth Investor Conference
08 Mar 2022 //
BUSINESSWIRE
GlycoMimetics Reports Financial Results for Fourth Quarter and Full Year 2021
03 Mar 2022 //
BUSINESSWIRE
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
03 Mar 2022 //
BUSINESSWIRE
GlycoMimetics to Report Q4 and 2021 Year-End Financial Results on March 3, 2022
25 Feb 2022 //
BUSINESSWIRE
GlycoMimetics Appoints Bruce Johnson SVP and CCO
23 Feb 2022 //
BUSINESSWIRE
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
23 Feb 2022 //
BUSINESSWIRE
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
24 Nov 2021 //
BUSINESSWIRE
Apollomics Begins Dosing in Phase 3 Trial in GlycoMimetics’ Uproleselan for AML
23 Nov 2021 //
BUSINESSWIRE
GlycoMimetics Appoints Lisa DeLuca as Vice President, Regulatory Affairs
22 Nov 2021 //
BUSINESSWIRE
GlycoMimetics Completes Enrollment of Phase 3 Registration
15 Nov 2021 //
BIOSPACE
GlycoMimetics Completes Enrollment of Phase 3 Trial Evaluating Uproleselan
15 Nov 2021 //
BUSINESSWIRE
GlycoMimetics GMI-1359 Data Selected for Presentation at 63rd ASH
11 Nov 2021 //
BUSINESSWIRE
GlycoMimetics to Report Third Quarter Financial Results on November 2, 2021
26 Oct 2021 //
BUSINESSWIRE
GlycoMimetics shares jump 12% after highlighting promising data
23 Sep 2021 //
SEEKINGALPHA
GlycoMimetics to Present at Upcoming H.C. Wainwright & Co Investment Conference
08 Sep 2021 //
BUSINESSWIRE
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
09 Aug 2021 //
BUSINESSWIRE
GlycoMimetics Names Harout Semerjian as New Chief Executive Officer
05 Aug 2021 //
BUSINESSWIRE
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2021
05 Aug 2021 //
BUSINESSWIRE
GlycoMimetics Names Harout Semerjian as New Chief Executive Officer
04 Aug 2021 //
BUSINESSWIRE
GlycoMimetics to Report Second Quarter Financial Results on August 5, 2021
29 Jul 2021 //
BUSINESSWIRE
Trial Launches to Evaluate GlycoMimetics’ Uproleselan Added to Cladribine
23 Jul 2021 //
BUSINESSWIRE
